NO315331B1 - Fremgangsmate for fremstilling av et konsentrat av anti-D- immunglobulin G samt farmasoytisk preparat inneholdende dette - Google Patents
Fremgangsmate for fremstilling av et konsentrat av anti-D- immunglobulin G samt farmasoytisk preparat inneholdende dette Download PDFInfo
- Publication number
- NO315331B1 NO315331B1 NO19945032A NO945032A NO315331B1 NO 315331 B1 NO315331 B1 NO 315331B1 NO 19945032 A NO19945032 A NO 19945032A NO 945032 A NO945032 A NO 945032A NO 315331 B1 NO315331 B1 NO 315331B1
- Authority
- NO
- Norway
- Prior art keywords
- igg
- plasma
- adsorbent
- ion exchange
- rhesus
- Prior art date
Links
- 229940027941 immunoglobulin g Drugs 0.000 title claims abstract description 5
- 238000000034 method Methods 0.000 title claims description 50
- 238000002360 preparation method Methods 0.000 title claims description 11
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 6
- 239000012141 concentrate Substances 0.000 title abstract description 8
- 239000003463 adsorbent Substances 0.000 claims abstract description 19
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 14
- 230000000694 effects Effects 0.000 claims abstract description 12
- 238000005342 ion exchange Methods 0.000 claims abstract description 9
- 125000000524 functional group Chemical group 0.000 claims abstract description 7
- 238000004255 ion exchange chromatography Methods 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000003599 detergent Substances 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 10
- 230000002779 inactivation Effects 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- -1 diethylaminoethyl groups Chemical group 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000007858 starting material Substances 0.000 claims description 6
- 239000004471 Glycine Substances 0.000 claims description 5
- 229940024546 aluminum hydroxide gel Drugs 0.000 claims description 5
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 claims description 5
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 108091005804 Peptidases Proteins 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 238000004440 column chromatography Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 238000011140 membrane chromatography Methods 0.000 claims description 3
- 238000005191 phase separation Methods 0.000 claims description 3
- 238000001179 sorption measurement Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 210000002381 plasma Anatomy 0.000 description 37
- 239000012064 sodium phosphate buffer Substances 0.000 description 18
- 239000000499 gel Substances 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 15
- 102000018358 immunoglobulin Human genes 0.000 description 15
- 239000000427 antigen Substances 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 238000005194 fractionation Methods 0.000 description 7
- 206010070834 Sensitisation Diseases 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 230000035935 pregnancy Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 238000005277 cation exchange chromatography Methods 0.000 description 5
- 239000006167 equilibration buffer Substances 0.000 description 5
- 229940072221 immunoglobulins Drugs 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920005654 Sephadex Polymers 0.000 description 4
- 239000012507 Sephadex™ Substances 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000011321 prophylaxis Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002616 plasmapheresis Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 239000001166 ammonium sulphate Substances 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000004941 influx Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010049466 Erythroblastosis Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101000894412 Mycolicibacterium paratuberculosis (strain ATCC BAA-968 / K-10) Bacterioferritin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 229940099472 immunoglobulin a Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000006353 oxyethylene group Chemical group 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
- C07K16/065—Purification, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93810912A EP0659767B2 (de) | 1993-12-27 | 1993-12-27 | Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält |
Publications (3)
Publication Number | Publication Date |
---|---|
NO945032D0 NO945032D0 (no) | 1994-12-23 |
NO945032L NO945032L (no) | 1995-06-28 |
NO315331B1 true NO315331B1 (no) | 2003-08-18 |
Family
ID=8215103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19945032A NO315331B1 (no) | 1993-12-27 | 1994-12-23 | Fremgangsmate for fremstilling av et konsentrat av anti-D- immunglobulin G samt farmasoytisk preparat inneholdende dette |
Country Status (20)
Country | Link |
---|---|
US (1) | US5593675A (da) |
EP (1) | EP0659767B2 (da) |
JP (1) | JP2926463B2 (da) |
KR (1) | KR100368563B1 (da) |
AT (1) | ATE175979T1 (da) |
AU (1) | AU682243B2 (da) |
CA (1) | CA2138921C (da) |
CZ (1) | CZ286271B6 (da) |
DE (1) | DE59309332D1 (da) |
DK (1) | DK0659767T4 (da) |
ES (1) | ES2129076T5 (da) |
FI (1) | FI112168B (da) |
GR (1) | GR3029817T3 (da) |
HU (1) | HU216864B (da) |
NO (1) | NO315331B1 (da) |
NZ (1) | NZ278057A (da) |
PL (1) | PL180358B1 (da) |
SI (1) | SI9420008B (da) |
TW (1) | TW311884B (da) |
WO (1) | WO1995018155A1 (da) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2198913T5 (es) * | 1998-05-06 | 2013-11-18 | Genentech, Inc. | Purificación de proteínas mediante cromatografía de intercambio iónico |
US6281336B1 (en) * | 1998-06-09 | 2001-08-28 | Statens Serum Institut | Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
DE19923027C2 (de) * | 1999-05-19 | 2002-09-19 | Aventis Behring Gmbh | Verfahren zur Inaktivierung von Viren |
US6475749B1 (en) * | 1999-08-11 | 2002-11-05 | The Regents Of The University Of California | Rh hybrid antibody |
SE0001128D0 (sv) * | 2000-03-30 | 2000-03-30 | Amersham Pharm Biotech Ab | A method of producing IgG |
ES2184594B1 (es) * | 2001-01-17 | 2004-01-01 | Probitas Pharma Sa | Procedimiento para la produccion de gammaglobulina g humana inactivada de virus. |
EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
CA2458750C (en) | 2004-02-23 | 2012-02-07 | Bayer Inc. | Isoolefin-diolefin production process and apparatus therefor |
US20060263357A1 (en) * | 2005-05-05 | 2006-11-23 | Tedder Thomas F | Anti-CD19 antibody therapy for autoimmune disease |
TWI391399B (zh) | 2005-05-25 | 2013-04-01 | Hoffmann La Roche | 測定溶離多肽之鹽濃度之方法 |
EA017152B1 (ru) * | 2006-08-28 | 2012-10-30 | Арес Трейдинг С.А. | СПОСОБ ОЧИСТКИ Fc-СОДЕРЖАЩИХ БЕЛКОВ |
BRPI0716139A2 (pt) * | 2006-08-28 | 2013-09-17 | Ares Trading Sa | processo para purificaÇço de proteÍnas de fusço fc |
IT1397061B1 (it) * | 2009-12-28 | 2012-12-28 | Kedrion Spa | Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale. |
WO2011095543A1 (en) | 2010-02-04 | 2011-08-11 | Csl Behring Ag | Immunoglobulin preparation |
EP2361636A1 (en) | 2010-02-26 | 2011-08-31 | CSL Behring AG | Immunoglobulin preparation and storage system for an immunoglobulin preparation |
RU2467783C2 (ru) * | 2010-07-30 | 2012-11-27 | Закрытое акционерное общество "БиоХимМак СТ" | Способ хроматографического выделения иммуноглобулина |
PT2616090T (pt) * | 2010-09-17 | 2023-10-16 | Takeda Pharmaceuticals Co | Estabilização de imunoglobulinas através de formulação aquosa com histidina em ph fracamente ácido a neutro |
TWI610937B (zh) | 2011-08-26 | 2018-01-11 | 巴克斯歐塔公司 | 用於降低血漿來源免疫球蛋白組成物之血栓性栓塞可能性的方法 |
AU2013203043B2 (en) * | 2013-03-15 | 2016-10-06 | Takeda Pharmaceutical Company Limited | Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs |
EP3118210B1 (en) * | 2014-03-11 | 2019-11-13 | Green Cross Holdings Corporation | Method for purifying immunoglobulin |
WO2015137530A1 (ko) * | 2014-03-11 | 2015-09-17 | 주식회사 녹십자홀딩스 | 면역글로불린의 정제방법 |
EP4349859A1 (en) * | 2023-01-27 | 2024-04-10 | CSL Behring AG | Method to purify anti-d immunoglobulin g from plasma |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869436A (en) * | 1971-06-01 | 1975-03-04 | Statens Bakteriologiska Lab | Method for fractionating plasma proteins using peg and ion-exchangers |
ATE19735T1 (de) * | 1982-02-08 | 1986-05-15 | Schweiz Serum & Impfinst | Intravenoes verabreichbares humanes immunglobulin und verfahren zu dessen herstellung. |
US4434093A (en) * | 1982-07-26 | 1984-02-28 | Ortho Diagnostic Systems Inc. | Methods for preparation of HBs Ag free gamma globulins |
DE3640513A1 (de) * | 1986-11-27 | 1988-06-09 | Biotest Pharma Gmbh | Verfahren zur herstellung eines virussicheren, lagerstabilen und intravenoes vertraeglichen immunglobulin-g-praeparates |
US5118796A (en) * | 1987-12-09 | 1992-06-02 | Centocor, Incorporated | Efficient large-scale purification of immunoglobulins and derivatives |
US5138034A (en) * | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
US5177194A (en) * | 1990-02-01 | 1993-01-05 | Baxter International, Inc. | Process for purifying immune serum globulins |
-
1993
- 1993-12-27 DK DK93810912T patent/DK0659767T4/da active
- 1993-12-27 AT AT93810912T patent/ATE175979T1/de active
- 1993-12-27 ES ES93810912T patent/ES2129076T5/es not_active Expired - Lifetime
- 1993-12-27 DE DE59309332T patent/DE59309332D1/de not_active Expired - Lifetime
- 1993-12-27 EP EP93810912A patent/EP0659767B2/de not_active Expired - Lifetime
-
1994
- 1994-12-21 US US08/360,334 patent/US5593675A/en not_active Expired - Lifetime
- 1994-12-22 CZ CZ19952492A patent/CZ286271B6/cs not_active IP Right Cessation
- 1994-12-22 AU AU14143/95A patent/AU682243B2/en not_active Ceased
- 1994-12-22 CA CA002138921A patent/CA2138921C/en not_active Expired - Fee Related
- 1994-12-22 PL PL94310435A patent/PL180358B1/pl not_active IP Right Cessation
- 1994-12-22 SI SI9420008A patent/SI9420008B/sl unknown
- 1994-12-22 KR KR1019950703644A patent/KR100368563B1/ko not_active IP Right Cessation
- 1994-12-22 NZ NZ278057A patent/NZ278057A/en not_active IP Right Cessation
- 1994-12-22 HU HU9502514A patent/HU216864B/hu not_active IP Right Cessation
- 1994-12-22 WO PCT/EP1994/004267 patent/WO1995018155A1/en active IP Right Grant
- 1994-12-23 NO NO19945032A patent/NO315331B1/no not_active IP Right Cessation
- 1994-12-27 FI FI946103A patent/FI112168B/fi not_active IP Right Cessation
- 1994-12-27 JP JP6337017A patent/JP2926463B2/ja not_active Expired - Fee Related
-
1995
- 1995-01-10 TW TW084100147A patent/TW311884B/zh not_active IP Right Cessation
-
1999
- 1999-03-30 GR GR990400907T patent/GR3029817T3/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO315331B1 (no) | Fremgangsmate for fremstilling av et konsentrat av anti-D- immunglobulin G samt farmasoytisk preparat inneholdende dette | |
CA2239237C (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
US20070244305A1 (en) | Process for The Manufacture of Virus Safe Immunoglobulin | |
US6955917B2 (en) | Chromatographic method for high yield purification and viral inactivation of antibodies | |
EP3305800B1 (en) | Preparation method of plasma-derived hepatitis b human immunoglobulin agent | |
Hässig | Intravenous immunoglobulins: pharmacological aspects and therapeutic use | |
DK157367B (da) | Fremgangsmaade til fremstilling af intravenoest administrerbart humant immunoglobulin | |
Burnouf | What can be learned in the snake antivenom field from the developments in human plasma derived products? | |
CA2375560A1 (en) | Manufacturing method for intravenous immune globulin and resultant product | |
Berger et al. | From subcutaneous to intravenous immunoglobulin and back | |
Burnouf | Preprint of a manuscript published in Toxicon | |
dans la Region | Ulllted States Patent [19][11] Patent Number: 6,069,236 | |
Yap | Humoral Functions of Immunoglobulin: Relationship to Purification Technology of Intravenous Immunoglobulin | |
MXPA99007835A (en) | Production process for intravenous immune serum globulin and resultant product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |